Antiretroviral therapy and liver disorders in the OPERA^® cohort.

"Conflict of interest statement: This work was funded by ViiV Healthcare. MW has participated in post-conference advisory boards for the Conference on Retroviruses and Opportunistic Infections (CROI) and International AIDS Conference (IAC); serves as a principal investigator on ViiV Healthcare clinical trials but does not receive personal compensation for this work, which goes directly to the AIDS Healthcare Foundation; and is a member of the Epidemiology and Clinical Advisory Board for Epividian. KM has received research grants from Merck, Gilead Sciences, and Janssen; speaker honoraria from ViiV Healthcare, Merck, Gilead Sciences and Janssen; consultant fees from ViiV Healthcare, Gilead Sciences and Janssen; and advisory board participation of Epividian. LB, JF and GF are employed by Epividian, Inc.; Epividian has had research funded by ViiV Healthcare, Merck & Co., Inc. and Janssen Pharmaceutica. VV, NP, and MA are employed by ViiV Healthcare and hold stocks and shares in GlaxoSmithKline as part of their employment. LC is an employee and shareholder of GlaxoSmithKline. RH has received a research grant from Gilead, speaker honoraria and advisory boards from ViiV Healthcare, BMS, Merck, Gilead Sciences and Janssen, and advisory board participation of Epividian. PL is a member of the Epidemiology and Clinical Advisory Board for Epividian."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by ViiV Healthcare."